150.
Clinical Guidelines on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults--The Evidence Report. National Institutes of
Health
– 1998. – Vol. 6, № 2. – P. 51-209.
151.
Cohen B. Modulation of insulin activities by leptin / B. Cohen, D. Novick, M.
Rubinstein // Science. – 1997. – Vol. 274, № 5290. – P. 1185-1188.
152.
Collagen I and III and mechanical properties of conduit arteries in rats with
genetic hypertension / P. Chamiot Clerc [et al.] // J. Vasc. Res. – 1999. – Vol. 36,
№ 2. – P. 139-146.
153.
Comparative study of ACE inhibition, angiotensin AII antagonism, and
calcium channel blockade on flow-mediated vasodilation in patients with coronary
disease (BANFF study) / T. J. Anderson [et al.] // J. Am. Coll. Cardiol. – 2000. –
Vol. 35, № 1. – P. 60-66.
154.
Connective tissue accumulation in the left coronary artery of young SHR / P.
Anversa [et al.] // Hypertension. – 1984. – Vol. 6, № 4. – P. 526-529.
155.
Contribution of novel biomarkers to incident stable angina and acute coronary
syndrome: the PRIME Study /
[et al.] // Eur. Heart J. – 2008. – Vol.
29, № 16. – P. 1966-1974.
156.
Croom K. F. Modified – Release Nifedipine. A Review of the Use of Modified
– Release Formulations in the Treatment of Hypertension and Angina Pectoris /
K. F. Croom, K. Wellington // Drugs. – 2006. – Vol. 66. – P. 497-528.
157.
Definition of metabolic syndrome: report of the National Heart, Lung, and
Blood Institute. American Heart Association conference on scientific issues
related to definition / S. M. Grundy [et al.] // Circulation. – 2004. – Vol. 109, № 3.
– P. 433-438.
158.
DiBona G. F. The sympathetic nervous system and hypertension / G. F.
DiBona // Hypertension. – 2004. – Vol. 43, № 2. – P. 147-150.
159.
Different effect of a calcium-antagonist and a beta-blocker on nitric oxide
availability in essential hypertensive patients / S. Taddei [et al.] // J. Hypertens. –
1999. – Vol. 17. – P. 129-132.
